Tigermed vs WuXi AppTec

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/tigermedgrp/wuxiapptec

Category	Tigermed	WuXi AppTec
Listed site	cro	cro
Summary	Leading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.	Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Services	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Clinical Trial Services Clinical Imaging Core Lab Central Laboratory Services Medical Writing Pharmacovigilance & Drug Safety Biostatistics & Statistical Programming Data Management & eClinical Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy China NMPA Regulatory Strategy Japan PMDA Regulatory Strategy Device & Combination Product Services Translational Research GLP Toxicology In Vitro ADME / DMPK In Vitro Pharmacology Preclinical In Vitro Studies In Vivo PK / PD Studies In Vivo Efficacy Models Preclinical In Vivo Studies Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Medicinal Chemistry High-Throughput Screening Oncology Specialty Services Cardiovascular & Metabolic Specialty Services CNS Specialty Services Immunology & Inflammation Services Virology Services Microbiology Services	Discovery Research Target Identification & Validation High-Throughput Screening Medicinal Chemistry Computational & In-Silico Drug Discovery Protein Engineering Preclinical In Vitro Studies In Vitro Pharmacology In Vitro ADME / DMPK Safety Pharmacology Genetic Toxicology Preclinical In Vivo Studies In Vivo Efficacy Models In Vivo PK / PD Studies GLP Toxicology Carcinogenicity Studies DART (Reproductive & Developmental Toxicology) Specialized & Large-Animal Models Bioanalysis LC-MS Bioanalysis (Small Molecule) Ligand-Binding Bioanalysis (Large Molecule) Immunogenicity Assays (ADA / NAb) Biomarker Assays Flow Cytometry Services Clinical Trial Services Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy Analytical Method Development & Validation ICH Stability Studies Translational Research
Modalities	Small Molecule Biologics (Monoclonal Antibodies) Biologics (Other) Vaccine Cell Therapy Gene Therapy Radiopharmaceutical Oligonucleotide Peptide	Small Molecule Peptide Oligonucleotide Biologics (Monoclonal Antibodies) Biologics (Other) Antibody-Drug Conjugate (ADC) mRNA Cell Therapy Gene Therapy Vaccine
Indications	Oncology Cardiovascular Neurology Immunology Infectious Disease Rare Disease Metabolic Ophthalmology Gastroenterology Respiratory	Oncology Immunology Neurology Psychiatry Metabolic Cardiovascular Infectious Disease Rare Disease Respiratory Dermatology Ophthalmology Gastroenterology Nephrology Women's Health
Locations	Headquarters, Hangzhou, Zhejiang, China Global Offices, Multiple, Global, Multiple (180+ locations across 5 continents)	Headquarters, Shanghai, Pudong, China Global Operations, Asia, Europe, North America
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.